Physician

Lijo John, MD

According to 2025 Medicare claims, Lijo John, MD (NPI: 1295050037) practices internal medicine in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 75601-4717.

John's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 775 traditional Medicare patients, billed 149,644 HCPCS/CPT codes, and received $2,147,373 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,606 prescription claims across 254 beneficiaries totaling $4,162,745 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 12 claims. Open Payments data shows 32 records totaling $141,153. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $25,010 to $4,162,745. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,319 and ending at $1,721.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.8M$3.6M2015 Medicare payment: $259,259 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $742,538 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,384,881 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,753,324 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $3,552,197 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $3,402,525 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,998,120 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,982,520 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,419,165 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,147,373 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201512515,396$259,259
201652947,910$742,538
201771380,461$1,384,881
2018874161,611$2,753,324
20191,020216,591$3,552,197
20201,024220,136$3,402,525
2021953188,876$2,998,120
2022933206,472$2,982,520
2023773178,275$2,419,165
2024775149,644$2,147,373

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$2.1M$4.2M2015 Drug cost: $25,010 (USD; Tot_Drug_Cst)2016 Drug cost: $190,052 (USD; Tot_Drug_Cst)2017 Drug cost: $683,156 (USD; Tot_Drug_Cst)2018 Drug cost: $1,620,408 (USD; Tot_Drug_Cst)2019 Drug cost: $2,512,679 (USD; Tot_Drug_Cst)2020 Drug cost: $3,838,635 (USD; Tot_Drug_Cst)2021 Drug cost: $4,040,243 (USD; Tot_Drug_Cst)2022 Drug cost: $3,483,158 (USD; Tot_Drug_Cst)2023 Drug cost: $3,768,492 (USD; Tot_Drug_Cst)2024 Drug cost: $4,162,745 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201560141$25,010
2016123426$190,052
2017159742$683,156
20182101,233$1,620,408
20192771,740$2,512,679
20203312,060$3,838,635
20213022,001$4,040,243
20222801,855$3,483,158
20232991,885$3,768,492
20242541,606$4,162,745

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$6.2K$12K2016 Medicare payment: $8,668 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $12,453 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $12,479 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $3,687 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $506 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $561 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $905 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $4,307 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/RN/RN/R
2016N/R11$8,668
2017N/R19$12,453
2018N/R66$12,479
2019N/R27$3,687
2020N/R11$506
2021N/R24$561
2022N/R11$905
2023N/R12$4,307
2024N/RN/RN/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more198267$60
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's193413$12
80053Blood test, comprehensive group of blood chemicals341892$10
36415Insertion of needle into vein for collection of blood sample3471,139$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count330869$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RevlimidLenalidomide551,449$902,861
LenalidomideLenalidomide33924$485,355
LenvimaLenvatinib Mesylate16480$463,216
PomalystPomalidomide15420$350,866
NubeqaDarolutamide19570$221,611

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.22$399AstraZeneca Pharmaceuticals LP
Research PaymentsReported research-related payment or transfer-of-value amount.10$140,753Eli Lilly and Company
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Lijo John, MD?

Tedicare shows public-source Medicare data for Lijo John, MD (NPI 1295050037), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lijo John, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Lijo John, MD?

Lijo John, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Lijo John, MD have Open Payments data?

Lijo John, MD has 32 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.